Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don’t succeed. For example, after five long years the AC Immune SA (NASDAQ:ACIU) share price is a whole 52% lower. That’s an unpleasant experience for long term holders. And it’s not just long term holders hurting, because the stock is down 35% in the last year. The falls have accelerated recently, with the share price down 22% in the last three months. We note that the company has reported results fairly recently; and the market is hardly delighted. You can check out the latest numbers in our company report.

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they’ve been consistent with returns.

View our latest analysis for AC Immune

Because AC Immune made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. That’s because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Over half a decade AC Immune reduced its trailing twelve month revenue by 33% for each year. That puts it in an unattractive cohort, to put it mildly. Arguably, the market has responded appropriately to this business performance by sending the share price down 9% (annualized) in the same time period. We don’t generally like to own companies that lose money and don’t grow revenues. You might be better off spending your money on a leisure activity. You’d want to research this company pretty thoroughly before buying, it looks a bit too risky for us.

The company’s revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

This free interactive report on AC Immune’s balance sheet strength is a great place to start, if you want to investigate the stock further.

Investors in AC Immune had a tough year, with a total loss of 35%, against a market gain of about 11%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year’s performance may indicate unresolved challenges, given that it was worse than the annualised loss of 9% over the last half decade. We realise that Baron Rothschild has said investors should “buy when there is blood on the streets”, but we caution that investors should first be sure they are buying a high quality business. Shareholders might want to examine this detailed historical graph of past earnings, revenue and cash flow.